NovaQuest-backed Azurity Pharmaceuticals, a privately-held, specialty pharmaceutical company, agreed to acquire Arbor Pharmaceuticals, a specialty pharmaceutical company, from investment firms JW Asset Management and KKR. Financial terms were not disclosed. "On behalf of the Azurity and Arbor teams, I am delighted to announce this agreement and the potential it brings to our combined company. The combination of the two companies, each steeped in rich legacies, will create a one-of-a-kind company leveraging increased scale and diversification, a breadth of dosage forms, integrated capabilities, and expanded market presence to better serve our patients’ needs," Amit Patel, Azurity Chairman and CEO.